Follicle centre lymphoma follicular grade I II III

6 trials 2 recruiting MedDRA PT
6 Registered trials
2 Recruiting
5 Unique sponsors
5 Unique IMPs
5 Commercial trials
Drug classes (ATC)
— ATC code not specified 5
L Oncology (ATC L) 1
Mechanism of action (INN-stem analysis)
Monoclonal antibody (rat) 1 substance
BTK inhibitor 1 substance
Monoclonal antibody (chimeric) 1 substance
Unknown / small molecule 1 substance
Monoclonal antibody (tumor, humanized) 1 substance
Phase III: 3 Phase II: 2 Phase I/II: 1

Filter these 6 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 6 trials

Phase III

3 trials
  • BeOne Medicines AG Commercial
    ZANUBRUTINIB
    2022-502548-12-00 14 countries 2023 n=316
    Recruiting
  • Novartis Pharma AG Commercial
    IMP not specified
    2023-503452-27-00 7 countries 2024 n=58
    Ended
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB; RITUXIMAB
    2022-502113-28-00 8 countries 2024 n=220 Orphan
    Recruiting

Phase II

2 trials
  • Regeneron Pharmaceuticals Inc. Commercial
    ODRONEXTAMAB
    2024-511747-25-00 5 countries 2019 n=225 Orphan
    Ended
  • Oslo University Hospital HF Academic
    MOSUNETUZUMAB
    2022-500100-21-01 4 countries 2023 n=80
    Ended

Phase I/II

1 trial
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Regeneron Pharmaceuticals Inc. Commercial 2 Phase II, Phase III 1
BeOne Medicines AG Commercial 1 Phase III 1
Novartis Pharma AG Commercial 1 Phase III 0
Epizyme Inc. Commercial 1 Phase I/II 0
Oslo University Hospital HF Academic 1 Phase II 0
New trials by year
2019
1
2023
2
2024
2
← All indication landscapes